Page 116 - Read Online

Davidson et al. J Cancer Metastasis Treat 2021;7:45 https://dx.doi.org/10.20517/2394-4722.2021.77 Page 19 of 19

138. Enomoto K, Sato F, Tamagawa S, et al. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1. Sci
Rep 2019;9:14616. DOI PubMed PMC
139. Saha SK, Islam SMR, Abdullah-Al-Wadud M, Islam S, Ali F, Park KS. Multiomics analysis reveals that GLS and GLS2
differentially modulate the clinical outcomes of cancer. J Clin Med 2019;8:355. DOI PubMed PMC
140. Yu Y, Yu X, Fan C, et al. Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer. J Mol Med (Berl)
2018;96:777-90. DOI PubMed
141. Patel D, King T, Kebebew E, Nilubol N, Boufraqech M. Glutamine metabolism is a new potential therapeutic target in aggressive
thyroid cancer. J Endocr Soc 2019:3. DOI
142. De Amicis F, Perri A, Vizza D, et al. Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human
thyroid carcinoma cell lines. J Cell Physiol 2013;228:2054-62. DOI PubMed
143. Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol 2017;235:R43-61. DOI PubMed
144. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic
implications. Curr Cancer Drug Targets 2008;8:187-98. DOI PubMed
145. Lien EC, Lyssiotis CA, Cantley LC. Metabolic reprogramming by the PI3K-Akt-mTOR pathway in cancer. Recent Results Cancer
Res 2016;207:39-72. DOI PubMed
146. Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer
2020;20:74-88. DOI PubMed PMC
147. Chen G, Nicula D, Renko K, Derwahl M. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic
thyroid cancer cells and their stem cells. Oncol Rep 2015;33:1994-2000. DOI PubMed
148. Plews RL, Mohd Yusof A, Wang C, et al. A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin
Endocrinol Metab 2015;100:E748-56. DOI PubMed PMC
149. Metformin hydrochloride in mitigating side effects of radioactive iodine treatment in patients with differentiated thyroid cancer.
ClinicalTrials.gov identifier: NCT03109847. Available from: https://ClinicalTrials.gov/show/NCT03109847 [Last accessed on 23 Jun
2021].
150. Bachireddy P, Bendapudi PK, Felsher DW. Getting at MYC through RAS. Clin Cancer Res 2005;11:4278-81. DOI PubMed
151. Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res 2012;18:5546-53. DOI
PubMed PMC
152. Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci 2013;126:1713-9. DOI
PubMed PMC
153. Lee T, Yao G, Nevins J, You L. Sensing and integration of Erk and PI3K signals by Myc. PLoS Comput Biol 2008;4:e1000013. DOI
PubMed PMC
154. Enomoto K, Zhu X, Park S, et al. Targeting MYC as a therapeutic intervention for anaplastic thyroid cancer. J Clin Endocrinol Metab
2017;102:2268-80. DOI PubMed PMC
155. Sakr HI, Chute DJ, Nasr C, Sturgis CD. cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid
tumorigenesis. Diagn Pathol 2017;12:71. DOI PubMed PMC
156. Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL. A translational study "case report" on the small molecule "energy
blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr 2012;44:163-70.
DOI PubMed
157. Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective.
Mol Cancer 2018;17:154. DOI PubMed PMC
158. Park C, Perini J, Farmer RW, Fancy T, Monga M, Remick SC. Sorafenib and thyroid cancer. Expert Rev Endocrinol Metab
2014;9:561-70. DOI PubMed
159. Krajewska J, Handkiewicz-Junak D, Jarzab B. Sorafenib for the treatment of thyroid cancer: an updated review. Expert Opin
Pharmacother 2015;16:573-83. DOI PubMed
160. Borson-Chazot F, Dantony E, Illouz F, et al. Effect of buparlisib, a pan-class I PI3K inhibitor, in refractory follicular and poorly
differentiated thyroid cancer. Thyroid 2018;28:1174-9. DOI PubMed
161. Schneider TC, de Wit D, Links TP, et al. Everolimus in patients with advanced follicular-derived thyroid cancer: results of a phase II
clinical trial. J Clin Endocrinol Metab 2017;102:698-707. DOI PubMed
162. Hanna GJ, Busaidy NL, Chau NG, et al. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid
cancer: a phase II study. Clin Cancer Res 2018;24:1546-53. DOI PubMed
163. Harris EJ, Hanna GJ, Chau N, et al. Everolimus in anaplastic thyroid cancer: a case series. Front Oncol 2019;9:106. DOI PubMed
PMC
164. Sherman EJ, Dunn LA, Ho AL, et al. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of
radioactive iodine-refractory thyroid cancer. Cancer 2017;123:4114-21. DOI PubMed PMC